ERBB2 and breast carcinoma: The NOAH trial randomized 235 HER2 positive breast cancer patients to receive neoadjuvant chemotherapy with or without trastuzumab, with an increase from 22% with chemotherapy alone to 43% pCR with addition of trastuzumab (p = 0.0007) [23].